Your session is about to expire
← Back to Search
Atypical Antipsychotic
Lurasidone for Depression, Bipolar Disorder
Phase 4
Waitlist Available
Led By Martin Lan, MD PhD
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes
Awards & highlights
Summary
The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process. Participants will have two different brain scans (MRI and PET scan). They will also have treatment for your depression with an FDA approved medication, lurasidone (Latuda). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder.
Eligible Conditions
- Depression, Bipolar Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Montgomery Asberg Depression Rating Scale
Side effects data
From 2016 Phase 4 trial • 35 Patients • NCT0219974321%
Insomnia
21%
Sedation
14%
Stiffness in jaw
7%
diabetes mellitus
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lurasidone (LUR)
NONLUR
Trial Design
1Treatment groups
Experimental Treatment
Group I: LurasidoneExperimental Treatment1 Intervention
Open-label treatment with lurasidone within the dose range of 20-60 mg daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lurasidone
FDA approved
Find a Location
Who is running the clinical trial?
New York State Psychiatric InstituteLead Sponsor
477 Previous Clinical Trials
154,027 Total Patients Enrolled
Columbia UniversityOTHER
1,471 Previous Clinical Trials
2,536,349 Total Patients Enrolled
Martin Lan, MD PhDPrincipal InvestigatorColumbia University
Share this study with friends
Copy Link
Messenger